MANGOCEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Shareholders’ Equity
Mangoceutical, Inc. and Subsidiaries
Consolidated Statement of Changes in Stockholders’ Equity
For the Years Ended December 31, 2024 and 2023
| Additional · Total · Non- | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred B Stock · Preferred C Stock · Common Stock · Stock · Subscriptions · Paid-in · Accumulated · Comprehensive · Controlling · Stockholders’ | |||||||||||||||||||
| Shares · Amount · Shares · Amount · Shares* · Amount · Warrants · Receivable · Capital · Deficit · Loss · Interest · Equity | |||||||||||||||||||
| Balance, December 31, 2022 | - | $ | - | - | $ | - | 891,000 | 89 | $ | - | $ | - | $2,629,696 | $(2,015,756) | $ | - | $ | - | $614,029 |
| Issuance of common stock for services | - | - | - | - | 118,667 | 17 | - | - | 1,530,635 | - | - | - | 1,530,659 | ||||||
| Issuance of common stock for cash | - | - | - | - | 350,000 | 35 | - | - | 6,199,965 | - | - | - | 6,200,000 | ||||||
| Imputed interest related party loan repayment | - | - | - | - | - | - | - | - | (6,473) | - | - | - | (6,473) | ||||||
| Options and warrants vested for services | - | - | - | - | - | - | - | - | 624,463 | - | - | - | 624,463 | ||||||
| Warrants exercised | - | - | - | - | 68,300 | 7 | - | - | 1,024,493 | - | - | - | 1,024,493 | ||||||
| Net loss | - | - | - | - | - | - | - | - | - | (9,212,417) | (9,212,417) | ||||||||
| Balance, December 31, 2023 | - | $ | - | - | $ | - | 1,427,967 | $148 | $ | - | $ | - | $12,002,779 | $(11,228,173) | $ | - | $ | - | $774,754 |
| Issuance of preferred stock B for cash | 3,800 | - | - | - | - | - | 324,288 | (1,150,000) | 3,475,712 | - | - | - | 2,650,000 | ||||||
| Issuance of preferred stock C for patent acquisition | - | - | 980,000 | 98 | - | - | - | - | 14,209,902 | - | - | - | 14,210,000 | ||||||
| Issuance of common stock for services | - | - | - | - | 554,154 | 57 | - | - | 2,106,208 | - | - | - | 2,106,265 | ||||||
| Issuance of common stock for cash | - | - | - | - | 345,000 | 34 | - | - | 1,327,989 | - | - | - | 1,328,023 | ||||||
| Issuance of common stock for IP purchase | - | - | - | - | 515,000 | 52 | - | - | 1,344,098 | 1,344,150 | |||||||||
| Conversion of preferred stock B for common stock | (1,030) | - | - | - | - | - | - | - | (1,133,000) | - | - | - | (1,133,000) | ||||||
| Issuance of common stock for conversion of preferred stock B | - | - | - | - | 374,393 | 38 | - | - | 1,132,962 | - | - | - | 1,133,000 | ||||||
| Options and warrants vested for services | - | - | - | - | - | - | - | - | 248,682 | - | - | - | 248,682 | ||||||
| Preferred stock B dividend in common stock | - | - | - | - | 28,067 | 3 | - | - | 70,165 | (70,168) | - | - | - | ||||||
| Preferred stock C accrued dividend | 802,109 | (802,109) | - | ||||||||||||||||
| Reverse stock split rounding adjustment | - | - | - | - | 1,060 | (7) | - | - | 252 | - | - | - | 245 | ||||||
| Translation adjustment | - | - | - | - | - | - | - | - | - | - | (9,845) | - | (9,845) | ||||||
| Net loss | - | - | - | - | - | - | - | - | - | (8,706,145) | - | (1,081) | (8,707,226) | ||||||
| Balance, December 31, 2024 | 2,770 | - | 980,000 | 98 | 3,245,641 | 325 | 324,288 | (1,150,000) | 35,587,858 | (20,806,595) | (9,845) | (1,081) | 13,945,048 | ||||||
| * | Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 15 reverse stock split. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.